Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Strock

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Assay and Drug Development Technologies|September 9, 2016
Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC ScreenAshley T Fancher, Yun Hua, Daniel P Camarco, et al.
Assay and Drug Development Technologies|August 16, 2018
High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate CancerAshley T Fancher, Yun Hua, Daniel P Camarco, et al.
Experimental Cell Research|December 2, 2004
GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout miceJong-In Park, James F Powers, Arthur S Tischler, et al.
The Journal of Clinical Endocrinology and Metabolism|November 3, 2005
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancerChristopher J Strock, Jong-In Park, D Marc Rosen, et al.
Cancer Research|August 4, 2006
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cellsChristopher J Strock, Jong-In Park, Eric K Nakakura, et al.
Cancer Research|May 21, 2010
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signalingGeorg Feldmann, Anjali Mishra, Seung-Mo Hong, et al.
Cancer Research|September 23, 2003
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growthChristopher J Strock, Jong-In Park, Mark Rosen, et al.
SLAS Discovery : Advancing Life Sciences R & D|August 7, 2023
Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancerAshley T Fancher, Yun Hua, David A Close, et al.
Assay and Drug Development Technologies|July 29, 2010
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2Drew D Dudgeon, Sunita N Shinde, Tong Ying Shun, et al.
Journal of Biomolecular Screening|July 20, 2010
Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hitsDrew D Dudgeon, Sunita Shinde, Yun Hua, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Assay and Drug Development Technologies|September 9, 2016
Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC ScreenAshley T Fancher, Yun Hua, Daniel P Camarco, et al.
Assay and Drug Development Technologies|August 16, 2018
High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate CancerAshley T Fancher, Yun Hua, Daniel P Camarco, et al.
Experimental Cell Research|December 2, 2004
GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout miceJong-In Park, James F Powers, Arthur S Tischler, et al.
The Journal of Clinical Endocrinology and Metabolism|November 3, 2005
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancerChristopher J Strock, Jong-In Park, D Marc Rosen, et al.
Cancer Research|August 4, 2006
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cellsChristopher J Strock, Jong-In Park, Eric K Nakakura, et al.
Cancer Research|May 21, 2010
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signalingGeorg Feldmann, Anjali Mishra, Seung-Mo Hong, et al.
Cancer Research|September 23, 2003
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growthChristopher J Strock, Jong-In Park, Mark Rosen, et al.
SLAS Discovery : Advancing Life Sciences R & D|August 7, 2023
Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancerAshley T Fancher, Yun Hua, David A Close, et al.
Assay and Drug Development Technologies|July 29, 2010
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2Drew D Dudgeon, Sunita N Shinde, Tong Ying Shun, et al.
Journal of Biomolecular Screening|July 20, 2010
Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hitsDrew D Dudgeon, Sunita Shinde, Yun Hua, et al.
Pageof 3